ANRO

Alto Neuroscience, Inc. is a clinical-stage biotechnology company developing precision psychiatry treatments using brain biomarkers to match patients with targeted therapies. The company's approach uses electroencephalography (EEG) and machine learning to identify brain-based biomarkers that predict which patients will respond to specific psychiatric treatments. Alto's pipeline includes drug candidates for major depressive disorder, insomnia, post-traumatic stress disorder, and other psychiatric conditions. The company's precision medicine platform aims to improve treatment outcomes by selecting therapies based on individual brain activity patterns rather than trial-and-error prescribing. Alto Neuroscience's approach addresses the significant unmet need in psychiatry, where current treatments have low response rates and long time-to-effect. Founded in 2019 and headquartered in Los Altos, California, Alto represents the emerging field of precision psychiatry. The company's success depends on clinical trial outcomes, regulatory approvals, and validation of biomarker-guided treatment selection in psychiatric care.